In vivo and in vitro effects of RAD001 on bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1212-1221

  Vasconcelos Nóbrega, Carmen ^a   Pinto Leite, Rosario ^b   Arantes Rodrigues, Regina ^c   Ferreira, Rita ^d   Brochado, Paulo ^e   Cardoso, Maria L ^f   Palmeira, Carlos ^g,h   Salvador, Alexandre ⁱ   Guedes Teixeira, Catarina I ^c   Colaço, Aura ^c   Palomino, Luis F ^j   Lopes, Carlos ^f   Santos, Lúcio ^g,h   Oliveira, Paula A ^c  

^a POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

^b Hospital Center of Tras os Montes and Alto Douro   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^d UNIVERSITY OF AVEIRO   (Portugal)

^e HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^h UNIVERSIDADE FERNANDO PESSOA   (Portugal)

ⁱ UNIVERSITY OF LISBON   (Portugal)

^j UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

more..

Author keywords

Akt expressivity; Apoptosis; Bladder cancer cell lines; Mice; MTOR; N butyl N (4 hydroxybutyl) nitrosamine; Proliferation; RAD001

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AKT EXPRESSIVITY; APOPTOSIS; BLADDER CANCER CELL LINES; MICE; MTOR; N-BUTYL-N-(4-HYDROXYBUTYL) NITROSAMINE; PROLIFERATION; RAD001;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTYLHYDROXYBUTYLNITROSAMINE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED ICR; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 84884671137     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.11.002     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Winer E., Gralow J., Diller L., et al. Clinical Cancer Advances 2008: Major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2009, 27:812-826.
3. Stein J.P., Skinner D.G. Radical cystectomy for invasive bladder cancer: Long-term results of a standard procedure. World J Urol 2006, 3:296-304.
4. Crallan R.A., Georgopoulos N.T., Southgate J. Experimental models of human bladder carcinogenesis. Carcinogenesis 2006, 27:374-381.
5. Oliveira P.A., Colaço A., De la Cruz P.L., et al. Experimental bladder carcinogenesis-rodent models. Exp Oncol 2006, 28:2-11.
6. Oliveira P.A., Arantes-Rodrigues R., Sousa-Diniz C., et al. The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN. Anticancer Res 2009, 29:3221-3226.
7. Palmeira C., Lameiras C., Amaro T., et al. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa. Urol Oncol 2011, 29:205-211.
8. Ma W.W., Adjei A.A. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009, 59:111-137.
9. Seghal S.N. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003, 35(3 Suppl):7S-14S.
10. Edinger A.L., Linardic C.M., Chiang G.G., et al. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian Cells. Cancer Res 2003, 63:8451-8460.
11. Paghdal K., Schwartz R.A. Sirolimus (rapamycin): From the soil of Easter Island to a bright future. J Am Acad Dermatol 2007, 57:1046-1050.
12. Garcia J., Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008, 7:347-354.
13. Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004, 64:252-261.
14. Huang S., Bjornsti M., Houghton P.J. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003, 2:222-232.
15. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954-2963.
16. Augustine J.J., Hricik D.E. Experience with everolimus. Transplant P 2004, 36(Suppl 2S):500S-503S.
17. Kirchner G.I., Meier-Wiedenbach I., Manns M.P. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004, 43:83-95.
18. Janus A., Robak T., Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway. Its role in tumorigenesis and targeted antitumor therapy. Cell Mol Biol Lett 2005, 10:479-498.
19. Koehl G.E., Schlitt H.J., Geissler E.K. Rapamycin and tumor growth: Mechanism behind its anticancer activity. Transplant R 2005, 19:20-31.
20. Mabuchi S., Altomare D.A., Cheung M., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007, 13:4261-4270.
21. Epstein J.I., Amim B.M., Reuter V.R., et al. World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998, 22:1435-1448.
22. Videira P., Piteira A.R., Cabral M.G., et al. Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines. Urol Int 2001, 86:95-101.
23. Perabo F.G.E., Lindner H., Schmidt D., et al. Preclinical evaluation of gemcitabine/paclitaxel interactions in human bladder cancer lines. Anticancer Res 2003, 23:4805-4814.
24. Pinto-Leite R., Botelho P., Ribeiro E., et al. Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Can Res 2009, 28:3.
25. Fechner G., Claβen K., Schmidt D., et al. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder bancer. Urology 2009, 73:665-668.
26. Tang Z.Y., Wu Y.L., Gao S.L., et al. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J Surg Res 2008, 145:111-123.
27. Mansure J.J., Nassim R., Chevalier S., et al. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009, 8:2339-2347.
28. Markman B., Dienstmann R., Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010, 1:530-543.
29. Chiong E., Lee I.-L., Dadbin A., et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 2011, 17:2863-2873.
30. Tickoo S., Satish K., Milowsky M.I., et al. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: Possible therapeutic implications. BJU Int 2011, 107:844-849.